Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 21, 2021 08:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion to Present at the 40th Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
December 14, 2021 08:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion to be added to NASDAQ Biotechnology Index

REDWOOD CITY, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
November 10, 2021 14:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion to Participate in Two Upcoming Investor Conferences

REDWOOD CITY, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
November 04, 2021 10:49 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Publishes Abstract on BMF-219 at ASH Annual Meeting

BMF-219 displays global disruption of menin, highlighting ‘219’s novel mechanism of actionMolecule elicits broad impact on the complexes surrounding menin, resulting in strong modulation of MYC...
November 03, 2021 08:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Reports Third Quarter 2021 Financial Results and Business Highlights

Announced FDA clearance of Investigational New Drug Application (IND) for BMF-219, the company’s first development candidate from the FUSION platformPhase I trial to enroll adult patients with...
September 16, 2021 13:35 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces FDA Clearance of Investigational New Drug Application for Irreversible Menin Inhibitor BMF-219

Biomea Fusion to transform to a Clinical Stage Company with First in Human (FIH) Clinical TrialBMF-219 advances as the first clinical stage therapeutic from the company’s deep pipeline of covalent...
August 11, 2021 16:05 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Reports Second Quarter 2021 Financial Results and Business Highlights

Completed investigational new drug (“IND”) enabling studies for lead program, BMF-219, an irreversibly binding menin inhibitor. On track to complete IND submission for Phase I/II study of BMF-219 as...
June 28, 2021 19:10 ET | Source: Biomea Fusion, Inc.

BIOMEA Fusion Strengthens its Executive Team with Appointment of Franco Valle as Chief Financial Officer

REDWOOD CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery and development of...
May 27, 2021 16:05 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Reports First Quarter 2021 Financial Results and Business Highlights

-- Received $167 million in aggregate gross proceeds in April from initial public offering -- – Advancing lead oncology program BMF-219, a small molecule irreversible menin inhibitor, toward IND...
April 20, 2021 16:05 ET | Source: Biomea Fusion, Inc,

Biomea Announces Closing of Initial Public Offering

REDWOOD CITY, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery, development and...